Roche enters $1.15 billion licensing deal for Sarepta gene therapy

ZURICH (Reuters) – Roche (S:) entered into a $1.15 billion licensing agreement with Sarepta Therapeutics (O:) to obtain the right to launch and commercialize Sarepta’s investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States.

Roche will make an upfront payment of $750 million in cash and $400 million worth in equity at closing for Sarepta’s investigational micro-dystrophin gene therapy SRP-9001 that is currently in clinical development, the Swiss drugmaker said in a statement on Monday.

In addition, Sarepta is eligible to receive up to $1.7 billion in regulatory and sales milestones, plus royalties on net sales, Roche said, adding the agreement was expected to close in the first quarter of 2020.

Sarepta will continue to be responsible for the clinical development and manufacturing of SRP-9001 while sharing global clinical development costs equally with Roche.

DMD is a rare degenerative neuromuscular disorder, affecting about one in 3,500-5,000 male births worldwide and causing severe progressive muscle loss and premature death, Roche said.

Earlier this month, Sarepta gained U.S. approval for another DMD drug, Vyondys 53.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.